Pediatric Midazolam Dosing
For sedation/anxiolysis in children >1 month, use IV midazolam 0.05-0.1 mg/kg (max 5 mg) over 2-3 minutes for ages 6 months-5 years, or 0.025-0.05 mg/kg for ages 6-12 years; oral midazolam 0.25-0.5 mg/kg (max 20 mg) with children <6 years potentially requiring up to 1 mg/kg; IM midazolam 0.2 mg/kg (max 6 mg) for seizures; and intranasal midazolam 0.4-0.5 mg/kg for procedural sedation.
Route-Specific Dosing
Intravenous Administration
For sedation/anxiolysis prior to procedures 1, 2:
6 months to 5 years: Initial 0.05-0.1 mg/kg over 2-3 minutes
- Total dose up to 0.6 mg/kg may be needed (usually ≤6 mg total)
- Higher doses increase risk of prolonged sedation and hypoventilation
6 to 12 years: Initial 0.025-0.05 mg/kg over 2-3 minutes
- Total dose up to 0.4 mg/kg may be needed (usually ≤10 mg total)
12 to 16 years: Dose as adults
- Usually does not exceed 10 mg total
<6 months: Limited data; use extreme caution with small incremental doses due to high risk of airway obstruction and hypoventilation 2
Critical administration principles: Administer over 2-3 minutes, then wait an additional 2-3 minutes before repeating doses, as midazolam takes approximately three times longer than diazepam to achieve peak EEG effects 1, 2. Titrate in small increments every 3-5 minutes to avoid oversedation 1.
For rapid sequence intubation: 0.2 mg/kg IV; lower doses are ineffective. Allow 2-3 minutes for effect before administering muscle relaxant 1.
For refractory status epilepticus: Loading dose 0.15-0.2 mg/kg, followed by continuous infusion starting at 1 mcg/kg/min (0.06 mg/kg/hr), increasing by 1 mcg/kg/min increments every 15 minutes up to maximum 5 mcg/kg/min until seizures stop 1.
Oral Administration
0.25-0.5 mg/kg (maximum 20 mg) 1. Children <6 years may require up to 1 mg/kg 1. Recent evidence demonstrates that even 0.25 mg/kg produces satisfactory sedation in 97% of patients, with faster onset at higher doses but similar overall efficacy 3. The commercially prepared syrup has 95% acceptance rate and produces satisfactory anxiolysis in 86% at mask application 3.
Intramuscular Administration
For seizures: 0.2 mg/kg (maximum 6 mg per dose); may repeat every 10-15 minutes 1. Note that lorazepam is typically preferred for initial IV treatment of status epilepticus 1.
For sedation/anxiolysis: 0.1-0.15 mg/kg are usually effective without prolonging emergence from anesthesia. For more anxious patients, doses up to 0.5 mg/kg have been used, though total dose usually does not exceed 10 mg 2, 4.
Intranasal Administration
0.4-0.5 mg/kg for procedural sedation based on the most recent high-quality evidence 5. A 2025 randomized clinical trial using adaptive sequential selection methodology demonstrated that 0.4 and 0.5 mg/kg doses were optimal for laceration repair in children 6 months to 7 years, with both doses achieving adequate sedation without differences in adverse events 5. The 0.2 and 0.3 mg/kg doses were eliminated for insufficient efficacy 5.
However, EMS data suggests intranasal midazolam at 0.2 mg/kg may be associated with higher odds of requiring additional benzodiazepine doses compared to intramuscular administration 6, supporting the use of higher intranasal doses when feasible.
Buccal Administration
0.3 mg/kg demonstrated 84% efficacy in stopping seizures within 10 minutes, with 100% efficacy for seizures <30 minutes duration 7. Cessation occurred within median 3 minutes. This route offers practical advantages when IV access is unavailable 7.
Critical Safety Precautions
Respiratory monitoring is mandatory 1, 8. The most serious adverse events include hypoventilation, decreased oxygen saturation, apnea, and hypotension 1, 9. Studies show 26% of children with normal lungs developed decreased oxygen saturation (as low as 65%) after sedation, particularly when combined with opioids 10.
When combining with opioids, reduce initial doses of both medications 1, 2. There is increased incidence of apnea when midazolam is combined with other sedative agents 1.
Be prepared to provide respiratory support regardless of route 1. Have flumazenil available to reverse life-threatening respiratory depression, though note it will also reverse anticonvulsant effects and may precipitate seizures 1.
Age-specific vulnerabilities: Infants <6 months are particularly vulnerable to airway obstruction and hypoventilation, requiring titration with small increments and careful monitoring 2. Paradoxical agitation may occur, especially in younger children 1.
Dose adjustments required for: ASA class III-IV patients, children with special needs, anatomic airway abnormalities, moderate-to-severe tonsillar hypertrophy, and patients receiving P450-3A4 inhibitors (e.g., erythromycin) 8, 2.
Common Pitfalls
Inadequate waiting time between doses: Must wait 2-3 minutes after initial dose, then an additional 2-3 minutes to fully evaluate sedative effect before repeating 1, 2. Failure to wait leads to stacking doses and oversedation.
Rapid IV administration: Never administer as rapid IV bolus 2. Always give over 2-3 minutes to minimize respiratory depression and hypotension.
Insufficient intranasal dosing: Using 0.2 mg/kg intranasally may result in inadequate sedation and need for repeat dosing 5, 6. Use 0.4-0.5 mg/kg for procedural sedation.
Failure to reduce doses with co-administration: When using with opioids or other CNS depressants, initial doses of each must be reduced 1, 2.